UNASSIGNED: @entity1 suffering from @entity1491 ( @entity1491 ) have very limited treatment options. Sonidegib selectively inhibits the growth of Hedgehog pathway-dependent @entity5 and can treat locally advanced @entity1491 @entity1 who are not candidates for surgery or radiation therapy. The BOLT clinical trials were conducted to evaluate the efficacy/potency of sonidegib in the treatment of advanced @entity1491 or metastatic @entity1491 . The @entity1 were randomized in 1:2 ratios to receive 200 or 800 mg oral @entity40634 daily, stratified by disease, histological subtype and geographical region. The primary efficacy analyses showed that 18 @entity1 in the 200 mg group and 35 @entity1 in the 800 mg group show an objective response (Central Review Committee) that corresponds to 43% (95% confidence interval [CI]: 28-59) and 38% (95% CI: 28-48) in their respective categories. Disease control was found in 93% (39 @entity1 ) and 80% (74 @entity1 ) of the @entity1 administered 200 and 800 mg sonidegib, respectively. The adverse events were assessed by the Central Review Committee as well as the investigator review team as per the guidelines of National @entity5 Institute Common Terminology Criteria for Adverse Events version 4.03. The most frequently found adverse events reported in BOLT trials were @entity2473 , @entity1665 , @entity2342 (taste disturbance), @entity390 , elevated blood @entity908 kinase and fatigue. Comparatively, the @entity1 administered 200 mg sonidegib showed fewer adverse events than those in the 800 mg sonidegib category. Thus, the benefit of using the 200 mg dose of sonidegib outweighs the associated risks and it can be inferred that it would be judicious to choose doses of lesser strength.

Differential pharmacology and clinical utility of sonidegib in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1665 :: ('MESH:D000505', 'Disease') :: ['alopecia'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity40634 :: ('MESH:C561435', 'Chemical') :: ['sonidegib'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer', 'tumors'] @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine'] @entity2473 :: ('MESH:D013035', 'Disease') :: ['muscle spasms'] @entity2342 :: ('MESH:D004408', 'Disease') :: ['dysgeusia'] @entity1491 :: ('MESH:D002280', 'Disease') :: ['advanced basal cell carcinoma', 'BCC']
@entity1491 :: (MESH:D002280,Disease) :: ['advanced basal cell carcinoma']
